Evidence map›Paper›PMID 39492803›Full record

ArticleActa oncologica (Stockholm, Sweden)2024

Cancer incidence following non-neoplastic medical conditions: a prospective population-based cohort study.

Lauri J Sipilä, Tomas Tanskanen, Sanna Heikkinen, Karri Seppä, Mervi Aavikko, Janne Ravantti, Lauri A Aaltonen, Janne Pitkäniemi

Abstract read
In one paragraph

Article in Acta oncologica (Stockholm, Sweden), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lauri J SipiläDepartment of Medical and Clinical Genetics, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland; Applied Tumor Genomics, Research Programs Unit, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland; Finnish Cancer Registry, Helsinki, Helsinki, Finland.ORCID 0000-0001-8735-1783
Tomas TanskanenFinnish Cancer Registry, Helsinki, Helsinki, Finland.
Sanna HeikkinenFinnish Cancer Registry, Helsinki, Helsinki, Finland.ORCID 0000-0001-9995-5605
Karri SeppäFinnish Cancer Registry, Helsinki, Helsinki, Finland.
Mervi AavikkoDepartment of Medical and Clinical Genetics, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland; Applied Tumor Genomics, Research Programs Unit, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
Janne RavanttiDepartment of Medical and Clinical Genetics, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland; Applied Tumor Genomics, Research Programs Unit, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland; Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Finland.ORCID 0000-0002-8578-7230
Lauri A AaltonenDepartment of Medical and Clinical Genetics, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland; Applied Tumor Genomics, Research Programs Unit, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland.ORCID 0000-0001-6839-4286
Janne PitkäniemiFinnish Cancer Registry, Helsinki, Helsinki, Finland; Health Sciences Unit, Faculty of Social Sciences (Health Sciences), Tampere University, Tampere, Finland; Department of Public Health, Faculty of Medicine, University of Helsinki, Helsinki, Finland. janne.pitkaniemi@cancer.fi.ORCID 0000-0001-9879-6673

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeMany non-neoplastic diseases have been established to be tumorigenic, and cancers are sometimes misdiagnosed as non-neoplastic diseases. We conducted a comprehensive registry-based study of site-specific cancer diagnosis risk following the diagnosis of any preceding medical condition (PMC) encoded by the International Classification of Diseases (ICD)-10 classification. MATERIAL AND

methodsWe analyzed healthcare data and cancer data for a random population-based sample of 2.5 million individuals living in Finland on January 1, 2000. Hazard ratios for each PMC and cancer pair were estimated using piecewise constant hazard regression models. P-values were corrected for multiple testing with the Bonferroni method.

resultsSeveral lifestyle-related PMCs were associated with the risk of cancer diagnosis, exemplified by chronic obstructive pulmonary disease and subsequent lung cancer diagnosis risk (female hazard ratio [HR] = 9.91, 95% confidence interval [CI]: 9.18-19.7, p-adj. < 0.0001; male HR = 5.69, 95% CI: 5.43-5.96, p-adj. < 0.0001). Diagnosis risk of ill-defined cancers appeared to increase following diagnosis of Alzheimer's disease (AD). We identified rare PMCs of potential interest.

interpretationA considerable proportion of the statistically significant associations were explainable by tobacco smoking and alcohol use. The enrichment of ill-defined cancer diagnoses in persons with AD, together with the overall inverse association between AD and cancer, may reflect underdiagnosis of cancer in this patient population. Our results provide a useful resource for research on the prevention and early detection of cancer.

Indexed as

NeoplasmsRegistriesAdultAgedAged, 80 and overCohort StudiesFemaleFinlandHumansIncidenceMaleMiddle AgedProportional Hazards ModelsProspective StudiesPulmonary Disease, Chronic ObstructiveRisk Factors

Identifiers

PMID39492803
PMCPMC11541804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.